SurVaxM missed overall survival in newly diagnosed glioblastoma. MimiVax now wants FDA talks on a subgroup aged 65 and under.
Newly Diagnosed Glioblastoma Trial Misses Primary Survival Endpoint
read more
Clinical Trials
EGFR Exon 20 Insertion Trial Misses Its Primary Endpoint
ArriVent’s FURVENT Phase 3 missed its primary endpoint in EGFR exon 20 insertion lung cancer. LSDN examines the UK access position.
Pneumococcal Conjugate Vaccine Meets Phase 3 Goals, Two Serotypes Lag
Vaxcyte’s 31-valent pneumococcal conjugate vaccine met every primary endpoint in OPUS-1. It fell short on two serotypes against Capvaxive, and it meets a British adult programme that changed product this year.
Clinical Trials Roundup | 2 October 2026
The clinical trial results 2 October 2026 span hepatitis delta, wet macular degeneration, Niemann-Pick disease, COVID-19 and skin cancer. Mirum Pharmaceuticals’ brelovitug met its primary endpoint in chronic hepatitis delta. Kodiak Sciences’ Zenkuda and tabirafusp-ted...
Disease Progression Slowing Holds on Function, Misses on Composite
uniQure’s four-year AMT-130 results put disease progression slowing at 44 per cent on the composite scale and 61 per cent on functional capacity.
Merck Wnt Agonist Meets Diabetic Macular Oedema Treatment Goal
Merck’s remigromig met the BRUNELLO endpoint, but the diabetic macular oedema treatment package carries no figures and a retinopathy imbalance.
Ivonescimab Overall Survival Win Leaves the Key Numbers Undisclosed
Akeso has reported that ivonescimab beat pembrolizumab on overall survival in a Chinese Phase III trial. HARMONi-2 is the fourth Phase III trial of ivonescimab to meet an overall survival endpoint. The ivonescimab overall survival result is the first against...
Clinical Trials Roundup | 4 Sept 2026
Cytokinetics' aficamten meets both primary endpoints in the Phase 3 ACACIA-HCM trial in non-obstructive hypertrophic cardiomyopathy, Takeda and Protagonist's Mimrylo receives FDA approval as the first hepcidin mimetic for polycythaemia vera, Gilead's Bixlenvo is...
Autoimmune CAR-T Safety Under Review as Novartis Halts Eight Trials
Autoimmune CAR-T safety has moved to the centre of the cell therapy agenda. Novartis has halted eight clinical studies of its experimental CD19 CAR-T therapy rapcabtagene autoleucel. The company acted after three fatal cases of a severe inflammatory reaction. Bristol...
Screen Failures Are Data Too: What They Reveal About Trial Design
A single screen failure tells us something about a patient. A pattern of screen failures may tell us something about the trial. Clinical research is very good at studying the patients who make it into a trial. We analyze their baseline characteristics, laboratory...
Autogene Cevumeran Halt Redraws Cancer Vaccine Trial Design
BioNTech and Genentech have stopped a Phase 2 trial of autogene cevumeran in colorectal cancer. An independent data safety monitoring board recommended the termination. The companies confirmed the decision on 28 August 2026. It arrives nine days after a landmark...
Clinical Trials Roundup | 28 Aug 2026
Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...
Intismeran Autogene Phase 3 Win Moves Cancer Vaccines to Logistics
Merck and Moderna have reported what they describe as the first positive Phase 3 result for an individualised cancer therapy. Intismeran autogene, given with pembrolizumab, met its primary endpoint in resected melanoma. The companies announced the outcome on 19 August...
Clinical Trials Roundup | 21 Aug 2026
Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
The Next Recruitment Challenge Isn’t Awareness, It’s Qualification
For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...
Beyond Detection: What Our Microplastics Study Means for Clinical Practice
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
LSD Anxiety Data: Definium Hits All Phase 3 Endpoints
Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...
Panthera Opens New Clinical Research Clinic at Keele University
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...